<DOC>
	<DOCNO>NCT02178683</DOCNO>
	<brief_summary>This protocol evaluate Tacrolimus MMF condition fludarabine low-dose TBI patient candidate conventional allografting . A novel approach immunosuppression test incorporate early extend taper Tacrolimus start day +80 case relapse . The goal induce early immunity GVT effect without compromise GVHD control . The anti-metabolite MMF re-introduced day +100 try induce tolerance block chronic GVHD taper Tacrolimus . DLI may give presence disease progression mixed chimerism previous protocol .</brief_summary>
	<brief_title>Tacrolimus Mycophenolate Mofetil Post-Grafting Immunosuppression</brief_title>
	<detailed_description>OBJECTIVES Major Objectives A . To determine whether stable allogeneic hematopoietic engraftment safely establish patient receive non-myeloablative allogeneic SCT HLA-Identical non-identical family donor unrelated donor , fludarabine low-dose TBI , immunosuppression utilize tacrolimus MMF . B . To evaluate incidence grade II-IV GVHD associate treatment . C. To evaluate engraftment donor HLA-identical family member utilized allogeneic stem cell transplantation . D. To evaluate incidence GVHD use three time per day MMF unrelated donor stem cell transplant two time per day MMF family donor stem cell transplant . Minor Objectives A . To evaluate incidence chronic GVHD utilize Tac/MMF peripheral blood stem cell match mis-matched allogeneic donor . B . To evaluate disease response survival Flu/TBI allogeneic SCT .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients AML , ALL , CML , CLL , myelodysplastic syndrome ( MDS ) , NHL , Hodgkin 's disease ( HD ) , paroxysmal nocturnal hemoglobinuria ( PNH ) , hypoproliferative dysplasia without increased blast , myeloma , significantly high usual risk mortality conventional myeloablative allogeneic SCT due age comorbidities : Age ≥ 50 year AML ALL complete remission &lt; 18 % blast bone marrow Age ≥ 50 year MDS CML . Age 16 75 year lymphomas myeloma , fail chemotherapy candidate autologous transplant , fail prior autologous SCT . Patients age CLL lowgrade NHL . Patients CLL lowgrade NHL need fail least firstline treatment , alkylating agent , fludarabine 2chlorodeoxyadenosine ( 2CDA ) , antiCD20 monoclonal antibody rituximab . Patients age marrow failure Patients ≥60 year old first consider allogeneic stem cell transplant family member offer unrelated donor transplant suitable family member , preferably HLAmatched sibling , available . Patients hematological malignancy relapse prior auto transplantation . Patients highrisk ( &gt; 60 % ) relapse autologous transplantation hematological malignancy may receive allogeneic transplant `` consolidative immunotherapy '' . Diagnoses include MM , nonHL , HL , AML , ALL MDS . Minimal duration auto allo transplant 4 week . Patients age hematologic malignancy treatable allo SCT , , preexist medical condition disease ( Fanconi anemia PNH ) , consider significantly increase risk transplant toxicity use highdose transplantation regimen . Patients metastatic renal cell carcinoma . Must include good performance status ( Karnofsky score ≥ 60 % ) , active brain metastasis , life expectancy least 6 month , absence bulky liver metastasis . Patients treat active diseasespecific protocol available . Patients malignant disease treatable allogeneic SCT may eligible protocol case case basis , approve principal investigator BMT attend physician group . Available HLAidentical , oneantigen mismatch sibling donor , phenotypically HLAmatched family member , phenotypically match unrelated donor , 9/10 match unrelated donor . Age ≤ 75 year . Patients hematological malignancy eligible curative autologous SCT : intermediate highgrade NHL chemosensitive first relapse . HD chemosensitive first relapse . Otherwise healthy patient eligible conventional myeloablative allogeneic SCT . Patients rapidly progressive intermediate highgrade NHL , unless minimal disease state last treatment . Patients active uncontrolled CNS involvement malignancy . Fertile men woman unwilling use contraceptive technique 12 month follow treatment . Females pregnant . Patients HIV positive Organ dysfunction Left ventricle ejection fraction &lt; 35 % . DLCO &lt; 35 % predict , receive continuous supplementary oxygen . Liver function test : total bilirubin &gt; 2x upper limit normal , and/or transaminase &gt; 4x upper limit normal . Karnofsky score &lt; 50 patient &lt; 60 year , &lt; 70 patient age 60 69 year Creatinine clearance &lt; 60 ml/min . Patients hypertension poorly control antihypertensive therapy . Patients positive PRA antidonor T B cell ( + ) consider treatment protocol option available .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>TACROLIMUS</keyword>
	<keyword>MYCOPHENOLATE MOFETIL</keyword>
	<keyword>FLUDARABINE</keyword>
	<keyword>HLA-MATCHED</keyword>
	<keyword>MIS-MATCHED</keyword>
</DOC>